Advancing Medicines to Optimize Health Outcomes
At Gilead, we continue our legacy of making scientific breakthroughs in the pharmaceutical and medicine space.
We bring forward medicines in areas of unmet medical need through research and development and remain dedicated to developing innovative products for life-threatening illnesses that advance care for patients around the world.
The table below shows the list of Gilead’s registered pharmaceutical products in Hong Kong.
Disclaimer: The table is only for informational purpose and physician advice should be consulted.
| Product Name | Hong Kong Registration Number |
|---|---|
| AmBisome®amphotericin b liposome for injection 50 mg/vial | HK-43591 |
| Biktarvy®bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg | HK-65914 |
| Descovy®emtricitabine 200 mg / tenofovir alafenamide 10 mgemtricitabine 200 mg/ tenofovir alafenamide 25 mg | HK-64705 HK-64704 |
| Epclusa®sofosbuvir 400 mg/velpatasvir 100 mg | HK-65046 |
| Truvada®emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg | HK-56076 HK-57749 |
| Veklury® remdesivir 100 mg/vial | HK-66766 |
| Vemlidy®tenofovir alafenamide 25 mg | HK-65249 |
| Viread®tenofovir disoproxil fumarate 300 mg | HK-56075 HK-57750 |
| Vosevi®sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg | HK-65775 |